功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第1頁(yè)
功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第2頁(yè)
功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第3頁(yè)
功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第4頁(yè)
功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第5頁(yè)
已閱讀5頁(yè),還剩23頁(yè)未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用Role

of

routine

and

functional

Imaging(FI)Screening

and

diagnosis

of

neoplasmsPrecisestaging

of

malignancyResponse

assessment

of

cancer

treatmentMonitor

recurrencesBenefit

of

FIMajor

modalities

of

FI:positronemissiontomography(PET)combinedwithCTormagneticresonance(MR)imagingfMRI:

DWI,

DCE-MRI,

BOLD,

spectroscopy

etc.Emerging

techniques:

PET-MRI,

DKI,

IVIM,

APT,

CEST

etc.Offercomplementaryinformationincluding

metabolism

of

FDG,proliferation,hypoxia,andcellmembranesynthesisby

PEThypoxia

and

permeability

by

DCE

MRI

and

IVIM,cellproliferationandapoptosis

by

DWI,

IVIM

and

DKI,andepidermalgrowthfactorreceptorstatus.About

this

articlePart

I:

Discussesthepracticalaspectsofintegratingfunctionalimagingintohead-and-neckradiationtherapyplanning.Part

II:

Reviewsthepotentialofmolecularimagingbiomarkersforresponseassessmentandtherapyadaptation.Authors

concluded

that

FI

allowedmoreindividualizedtreatmentplanninginpatientswithheadandneckSCCsintheemergingeraofpersonalizedmedicine.Part

I

RoleofFunctionalImaginginRadiationTherapyPlanningTherewasa20%decreaseinOS

amongpatientswhounderwentradiationtherapywithaprotocolthatdidnotcomplywithestablishedinstitutionalstandards.Reasons:

Inaccuraciesintumortargetdelineation

Inter-observervariabilityin

clinical

practice

based

on

CT

fortargetdelineationFunctionalMRIandPETtechniquesprovidedifferentandpotentiallycomplementaryinformationaboutthetumorextentandbiologicactivity.PET-basedTumorTargetContouringTumoruptakeofPETradioactivetracerscanprovideexcellentcontrastresolutionbetweenneoplasticandnormaltissues.There

are

two

DOSE

CONTOURING

methods:

visualinterpretationandautomateddelineationmethods.Example

of

automateddelineationFigure2.SCCarisingfromtheepiglottis(T2N2bM0)ina67-year-oldman.AxialfusedFDGPET/CTimageshowstumorcontoursautomaticallygeneratedwithdiagnosticsoftware.Automated

delineation

is

believe

to

be

more

objective

than

visual

delineation.

Because,

analterationoftheSUVscalecanchangetheapparenttumorvolumeandleadtoincreasedinter-observervariability.Status

of

PET-contouring

at

presentAtpresent,thereisnoconsensusregardingtheoptimalcontouringmethod.ThemostpracticalapproachtodefiningthetumortargetistorelyonexpertvisualinterpretationsbynuclearmedicinephysiciansandradiologistsAnd

rely

onknowledgeofthelikelypatternsofdiseaseinfiltrationwithinstrictSUVscalelimits.However,limitedspatialresolutionandpartialvolumeeffectsblurtheedgesofFDG-avidtumorsatPET.PET-basedRadiationTherapyPlanningtheFDGPET–definedgrosstumorvolume(GTV)wasfoundtobesmallerandmoreaccuratethantheCT-orMRimaging–definedGTVandclosertothetumorvolumeatpathologicanalysis.however,nosingleimagingmodalityallowedperfectlyaccuratethree-dimensionalestimationofthetumorvolume.Allmodalitiesfailedtodetectabout10%ofthetumorvolume,mainlybecauseofsuperficialtumorextension.PETwasfoundtoallowtheidentificationofpotentialdiseaseextensionbeyondtheCT-definedGTVin29%–64%ofcases.PET-basedRadiationTherapyPlanningDuprezetal(24)demonstratedthefeasibilityofapplyingdoseescalationtoanFDGPET–avidGTVwithdosepaintingbynumbersinsteadofwithGTVcontouring.TheuseofmultimodalityimagingraisesthequestionofwhethertheGTVshouldbedefinedonthebasisofimagingwithonlyoneorwithseveralmodalities?

Thelackofconcordancefoundbetweenvariousimagingmodalitiessuggeststhatthesafestapproachwhendefiningatargetistouseallimagingmodalitiesalongwithphysicalexamination.

Anatomicandfunctionalimagingmodalitiescould

providedifferentbutcomplementaryinformationduringcontouring

and

planning

for

cancer

RT

treatment.Contourlinesarecolorcodedtoshowtheimagingmodalityonwhichtheyarebased(green=CT,blue=MRimaging,orange=PET).AdaptiveRadiationTherapyPlanningThereisconsiderableinterestinpersonalizingtreatmentinanattempttooptimizethetherapeuticratioforindividualpatients.Oneavenueforachievingthisistoalterthedeliveryofradiationtherapyonthebasisofchangesinthetumorand/ornormalorgansduringacourseoftreatment.Mainly

current

radiationtherapyisplannedatasinglepretreatmenttime-pointtodelineatethetargetvolumeandanyorgansatrisk,withnoaccounttakenofanatomicchangesduringthecourseoffractionatedradiationtherapy.AdaptiveRadiationTherapyPlanningGeetsetal

showedreductionsof51%intheclinicaltargetvolumeand48%intheplanningtargetvolumeafterapartialcourse(45-Gydose)ofradiationtherapy.InasubsequentstudyofpatientsreceivingCRT

therapyforlaryngopharyngealcancer,PET-basedandCT-basedprimarytumorGTVswerefoundtodecreaseatameanrateof3.2%and3.9%pertreatmentday,respectivelywhilenodalGTVsdecreasedatarateof2.2%pertreatmentday.Inaddition,positionalshiftswerenotedintheGTV.AdaptiveRadiationTherapyPlanningIt

providesanopportunitytoimprovethetherapeuticratiobyminimizingtheoveralldosetoorgansatriskandescalatingthedosetoareasoftumortissue.18F-fluorothymidine(FLT)PET/CTisanoninvasivemethodformonitoringproliferationduringtreatment.Troostetalshowedthatdecreasesintumor-relatedFLTuptakeoccurredearlyaftertheadministrationofthefifthradiationdosefraction.Bycontrast,changesintheCT-definedGTVweredetectableonlyafter4weeksofradiationtherapy.Thesedatademonstratedthefeasibilityofescalatingtheradiationdoseadministeredtotumorsub-volumeswithhighproliferativeactivityinthe2ndweekoftreatment.Figure6.Adaptivetherapyplanningina68-year-oldmanwithasupraglotticSCC(T2N2bM0)treatedwithchemoradiationtherapy.(a)AxialfusedPET/CTimageobtainedbeforethestartoftherapyshowsmarkedmetabolicactivity(SUVmax,22.2)inthetumor(arrowhead).(b)AxialfusedPET/CTimageobtainedafter11fractionsofradiationtherapyshowsareductionintumorsizeandmetabolicactivity(SUVmax,9.7).(c)AxialfusedPET/CTimage,obtainedafter21fractionsofradiationtherapy,showscontinuedreductionintumorsizeandmetabolicactivity(SUVmax,7.9).AdaptiveRadiationTherapyPlanningOther

limited

fMRI

data

alsosuggestthatchangesondiffusion-weightedordynamiccontrast-enhancedMRimagescouldbeusedtoguideadaptivedoseescalationstrategies.a

and

b

–beforec

and

d

–after

21

fractionshowthetumor(arrow)andnode(arrowhead)withreducedsignalintensityincandincreasedsignalintensityind,findingsindicativeofresponsetotreatment.Mainly

issues

of

FI

to

guide

A-RT

planning1、thechoiceofimagingmodality.2、imagingcharacteristicsmaynotbe

reproducibleatsuccessiveimagingevaluations.3、theoptimaltimingofimagingassessmentsduring

thecourseoftreatmentisunknown.4、theoptimalmethodfordefiningtumorcontours

isunclear.PART

II

FunctionalImagingforDiseaseResponseAssessmentfunctionalimagingappearstobeapromisingadditiontoclinicalexaminationandanatomicimagingforassessingtheresponseofheadandneckSCCtumorstoradiationtherapy.Thisisparticularlytrueintheclinicalscenarioofresidualmasses,whereanatomicimagingtechniquesareinaccurate.TheuseofFDGPETisnowsupportedbyconsiderabledata.ArolealsomaybeestablishedforotherPET-andMRimaging–basedtechniques.I

selected

fMRI

as

my

favorite

lecture

today.

While

leave

PET

for

colleaguefrom

nuclear

medicine

department.FunctionalMRImagingTechniquesAdvancedMRimagingtechniquessuchasdynamiccontrast-enhancedimaging,diffusion-weightedimagingbloodoxygenationlevel–dependent(BOLD)imagingspectroscopyholdthepromiseofprovidingfunctionalinformationaboutdisease.Thesetechniquescanbeusedforplanning,monitoring,andassessingtheresultsofradiationtherapyinpatientswithheadandneckSCCs.DynamicContrast-enhancedImagingitisanoninvasivetechniquethathelpscharacterizethemicrovasculature,therebyprovidingmarkersspecifictoperfusion,permeabilityofbloodvessels,andthevolumeofextracellularspace.Abnormalmicrovesselsseenatdynamiccontrast-enhancedMRimagingthemselvesmaybeamarkerofhypoxiaTumorangiogenesisisassociatedwithchaoticvesselformationandincompetentarteriovenousshunts,whichleadtolesseffectiveperfusionandamorehypoxicenvironmentthanexistsinnormaltissues.Previous

studies

of

DCE

MRINewboldetaldemonstratedastatisticallysignificantcorrelationbetweenvariousDCE-MRI

parameters,particularlyKtrans(whichrepresentsthepermeabilityofbloodvessels)andpimonidazolestaining(anexogenousmarkerforhypoxia).TheappearanceofheadandneckSCCsatdynamiccontrast-enhancedMRimagingalsohasbeenusedtosuccessfullypredicttreatmentresponsetochemoradiationtherapyinthetumors(85).(a)AxialT1-weightedMRimageobtainedforplanningofchemoradiationtherapyina62-year-oldmanshowsaprimarySCCintheleftaspectofthetonguebase(T4N2bM0)(arrow)andanodalmetastasis(arrowhead).(b,c)Axialdynamiccontrast-enhancedMRimagesbefore

and

after

RTshowincreasedvascularpermeability(Ktrans)beforeradiationtherapyintheprimarytumor(arrowinb)andcervicalnode(arrowheadinb)decreasedpermeabilityafter11fractionateddosesofradiationtherapyinthetumor(arrowinc)andnode(arrowheadinc).Thesefindingsareindicativeoftherapeuticresponse.Diffusion-weightedImagingDiffusion-weightedMRimagingisanoninvasiveimagingtechniquethatfacilitatestissuecharacterizationonthebasisofthemolecularmotionofwatermolecules.DiffusionisquantifiedbyusingtheADC,whichisinverselycorrelatedwithcellularityandisapotentialbiomarkerforapoptosis.TheincreaseddensityofcellswithinmalignantlymphnodesreducestheirADCatdiffusion-weightedMRimaging.StudieshaveshownthatDWIcanbeusefulfordifferentiatingsmallmalignantlymphnodesfromnonmalignantonesInonestudy,asensitivityof76%wasobtainedwiththeuseofADCatdiffusion-weightedimagingfordetectingsubcentimetriclymphnodemetastases,incomparisonwithasensitivityof7%obtainedwiththeuseofmorphologicfeaturesandsizedepictedatconventionalMRimagingInanotherstudy,in33patientswithheadandneckSCCs,changeinADCwasusedasamarkeroftumorresponsejust

1weekafterchemoradiationtherapy.Dirixetal(31)evaluatedtheusefulnessofDWIforradiationtherapyplanninga

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論